Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
6/17/26 Alkermes (ALKS) alixorexton for Narcolepsy Subscribers Only Subscribers Only Subscribers Only
6/15/26 Aptose (APTO) tuspetinib for Acute Myelogenous Leukemia (AML) Subscribers Only Subscribers Only Subscribers Only
6/15/26 Halia HT-6184 for Myelodysplastic Syndrome (MDS) Subscribers Only Subscribers Only Subscribers Only
6/14/26 Crinetics (CRNX) atumelnant for Congenital Adrenal Hyperplasia (CAH) Subscribers Only Subscribers Only Subscribers Only
6/14/26 Johnson & Johnson (JNJ) Tecvayli for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/17/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update